217 related articles for article (PubMed ID: 30692122)
1. Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib.
Latifi Y; Moccetti F; Wu M; Xie A; Packwood W; Qi Y; Ozawa K; Shentu W; Brown E; Shirai T; McCarty OJ; Ruggeri Z; Moslehi J; Chen J; Druker BJ; López JA; Lindner JR
Blood; 2019 Apr; 133(14):1597-1606. PubMed ID: 30692122
[TBL] [Abstract][Full Text] [Related]
2. The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear.
Loren CP; Aslan JE; Rigg RA; Nowak MS; Healy LD; Gruber A; Druker BJ; McCarty OJ
Thromb Res; 2015 Jan; 135(1):155-60. PubMed ID: 25527332
[TBL] [Abstract][Full Text] [Related]
3. Molecular Imaging of VWF (von Willebrand Factor) and Platelet Adhesion in Postischemic Impaired Microvascular Reflow.
Ozawa K; Packwood W; Varlamov O; Qi Y; Xie A; Wu MD; Ruggeri Z; López JA; Lindner JR
Circ Cardiovasc Imaging; 2018 Nov; 11(11):e007913. PubMed ID: 30571316
[TBL] [Abstract][Full Text] [Related]
4. Endothelial Cell-Derived Von Willebrand Factor, But Not Platelet-Derived, Promotes Atherosclerosis in Apolipoprotein E-Deficient Mice.
Doddapattar P; Dhanesha N; Chorawala MR; Tinsman C; Jain M; Nayak MK; Staber JM; Chauhan AK
Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):520-528. PubMed ID: 29348121
[TBL] [Abstract][Full Text] [Related]
5. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy.
Tersteeg C; de Maat S; De Meyer SF; Smeets MW; Barendrecht AD; Roest M; Pasterkamp G; Fijnheer R; Vanhoorelbeke K; de Groot PG; Maas C
Circulation; 2014 Mar; 129(12):1320-31. PubMed ID: 24449821
[TBL] [Abstract][Full Text] [Related]
6. Removal of endothelial surface-associated von villebrand factor suppresses accelerate datherosclerosis after myocardial infarction.
Ozawa K; Packwood W; Muller MA; Qi Y; Xie A; Varlamov O; McCarty OJ; Chung D; López JA; Lindner JR
J Transl Med; 2024 May; 22(1):412. PubMed ID: 38693516
[TBL] [Abstract][Full Text] [Related]
7. Elevated LDL Cholesterol Increases Microvascular Endothelial VWF and Thromboinflammation After Myocardial Infarction.
Ozawa K; Packwood W; Varlamov O; Muller M; Xie A; Wu MD; Abraham-Fan RJ; López JA; Lindner JR
Arterioscler Thromb Vasc Biol; 2023 Jun; 43(6):1041-1053. PubMed ID: 37128919
[TBL] [Abstract][Full Text] [Related]
8. Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory Response.
Hamadi A; Grigg AP; Dobie G; Burbury KL; Schwarer AP; Kwa FA; Jackson DE
Thromb Haemost; 2019 Jul; 119(7):1112-1123. PubMed ID: 31079415
[TBL] [Abstract][Full Text] [Related]
9. [French Chronic Myeloid Leukemia Intergroup 2022 recommendations for managing the risk of cardiovascular events on ponatinib in chronic myeloid leukemia].
Réa D; Messas E; Mirault T; Nicolini FE
Bull Cancer; 2022; 109(7-8):862-872. PubMed ID: 35725593
[TBL] [Abstract][Full Text] [Related]
10. Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.
Okabe S; Tauchi T; Kimura S; Maekawa T; Kitahara T; Tanaka Y; Ohyashiki K
PLoS One; 2014; 9(2):e89080. PubMed ID: 24586514
[TBL] [Abstract][Full Text] [Related]
11. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
Parker WT; Yeung DT; Yeoman AL; Altamura HK; Jamison BA; Field CR; Hodgson JG; Lustgarten S; Rivera VM; Hughes TP; Branford S
Blood; 2016 Apr; 127(15):1870-80. PubMed ID: 26773037
[TBL] [Abstract][Full Text] [Related]
12. All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.
Cassuto O; Dufies M; Jacquel A; Robert G; Ginet C; Dubois A; Hamouda A; Puissant A; Luciano F; Karsenti JM; Legros L; Cassuto JP; Lenain P; Auberger P
Oncotarget; 2012 Dec; 3(12):1557-65. PubMed ID: 23238683
[TBL] [Abstract][Full Text] [Related]
13. Myocardial Infarction Produces Sustained Proinflammatory Endothelial Activation in Remote Arteries.
Moccetti F; Brown E; Xie A; Packwood W; Qi Y; Ruggeri Z; Shentu W; Chen J; López JA; Lindner JR
J Am Coll Cardiol; 2018 Aug; 72(9):1015-1026. PubMed ID: 30139430
[TBL] [Abstract][Full Text] [Related]
14. Molecular imaging of activated von Willebrand factor to detect high-risk atherosclerotic phenotype.
McCarty OJ; Conley RB; Shentu W; Tormoen GW; Zha D; Xie A; Qi Y; Zhao Y; Carr C; Belcik T; Keene DR; de Groot PG; Lindner JR
JACC Cardiovasc Imaging; 2010 Sep; 3(9):947-55. PubMed ID: 20846630
[TBL] [Abstract][Full Text] [Related]
15. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models.
Brill A; Fuchs TA; Chauhan AK; Yang JJ; De Meyer SF; Köllnberger M; Wakefield TW; Lämmle B; Massberg S; Wagner DD
Blood; 2011 Jan; 117(4):1400-7. PubMed ID: 20959603
[TBL] [Abstract][Full Text] [Related]
16. Endothelial CD40 Mediates Microvascular von Willebrand Factor-Dependent Platelet Adhesion Inducing Inflammatory Venothrombosis in ADAMTS13 Knockout Mice.
Tahir S; Wagner AH; Dietzel S; Mannell H; Pircher J; Weckbach LT; Hecker M; Pohl U
Thromb Haemost; 2020 Mar; 120(3):466-476. PubMed ID: 32135568
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.
Kidoguchi K; Ureshino H; Kizuka-Sano H; Yamaguchi K; Katsuya H; Kubota Y; Ando T; Miura M; Takahashi N; Kimura S
Int J Hematol; 2021 Aug; 114(2):199-204. PubMed ID: 33907977
[TBL] [Abstract][Full Text] [Related]
18. Formation and Resolution of Pial Microvascular Thrombosis in a Mouse Model of Thrombotic Thrombocytopenic Purpura.
Adili R; Holinstat M
Arterioscler Thromb Vasc Biol; 2019 Sep; 39(9):1817-1830. PubMed ID: 31340669
[TBL] [Abstract][Full Text] [Related]
19. The N-terminal flanking region of the A1 domain regulates the force-dependent binding of von Willebrand factor to platelet glycoprotein Ibα.
Ju L; Dong JF; Cruz MA; Zhu C
J Biol Chem; 2013 Nov; 288(45):32289-32301. PubMed ID: 24062306
[TBL] [Abstract][Full Text] [Related]
20. Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management.
Saussele S; Haverkamp W; Lang F; Koschmieder S; Kiani A; Jentsch-Ullrich K; Stegelmann F; Pfeifer H; La Rosée P; Goekbuget N; Rieger C; Waller CF; Franke GN; le Coutre P; Kirchmair R; Junghanss C
Acta Haematol; 2020; 143(3):217-231. PubMed ID: 31590170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
